shelf(0)

No. 029 · Mind · Nootropic Peptide

Dihexa

PNB-0408N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S0
Compare Cite
Fingerprint 3 residues
Dihexa sequence fingerprint
  • Nonpolar 1
  • Polar 1
  • Modified / non-standard 1

Each dot is a residue placed around the ring from N- to C-terminus; its distance from the centre reflects its chemistry.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Evidence is limited to rodent studies (e.g. McCoy et al., JPET 2013); no published human studies.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Residues
3 amino acids, N→C
Molecular weight
504.7 Da
Formula
C27H44N4O5
Discovered
2013 Described as a metabolically stabilized angiotensin IV analogue (McCoy et al., JPET 2013).
Routes studied
Oral, Subcutaneous Routes used in published research
FDA
Not approved
WADA
Prohibited · S0 Non-approved substances
03

Sequence

N → C · 3 residues · hover, tap, or use arrow keys to inspect

04

Overview

A metabolically stabilized angiotensin IV analog (N-hexanoyl-Tyr-Ile-6-aminohexanoic amide) reported to act through hepatocyte growth factor (HGF)/c-Met signaling. Investigated in animal models of cognitive decline and dementia.

Research status Early-stage preclinical research; published animal studies showing cognitive restoration in impaired rats

05

Mechanism

Dihexa is a modified Tyr-Ile dipeptide derived from angiotensin IV, with an N-terminal hexanoyl cap and a C-terminal 6-aminohexanoic amide that improve metabolic stability and blood-brain barrier penetration. Rodent studies report that it potentiates hepatocyte growth factor (HGF) signaling through the c-Met receptor and increases hippocampal synaptogenesis.

06

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Potent synaptogenic activity
  • Enhanced memory formation and retrieval
  • Promoted neuronal connectivity
  • Potential cognitive rescue in impaired models
07

Safety & unknowns

No human safety data available. Only preclinical animal studies published. Extremely potent compound with unknown long-term effects. Theoretical risk of promoting tumor growth through HGF/c-Met signaling. Not FDA-approved. Use with extreme caution.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [1]

  1. Preclinical 2013

    Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents

    McCoy AT, Benoist CC, Wright JW, et al. Journal of Pharmacology and Experimental Therapeutics

    Describes the design of dihexa, an orally active, blood-brain barrier-permeant angiotensin IV analog that reversed cognitive deficits in scopolamine-treated and aged rats and increased hippocampal synaptogenesis.

    [pubmed] [doi]

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Dihexa. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/dihexa/

$ cite --format=bibtex 
@misc{peptidemeta-dihexa,
  title = {Dihexa},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/dihexa/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open